More than 3.1 million women within the Essence Patient Solutions network are at high risk for low bone density and fractures. These are patients who haven’t yet been activated. Many have never received a DXA scan, don’t understand their personal risk, and are unaware of available treatment options, including newer anabolic agents and selective estrogen receptor modulators (SERMs).
The consequences of inaction are serious: hip and spine fractures, chronic pain, reduced mobility, long-term disability, and elevated mortality risk.
But when bone health is addressed early, intervention works. The right treatment at the right time can reduce fracture risk, preserve independence, and improve long-term outcomes.
So why aren’t more women being treated? Because they’re not being reached in time.
Pharma marketers have a unique opportunity to close this care gap. By partnering with Essence, brands can deliver targeted, timely education to both patients and providers to drive awareness, improve diagnosis rates, and accelerate initiation of therapy. This is an opportunity to lead in a category where too many patients are still being overlooked.
The time to act is before the first fracture.